Arginine vasopressin modulates electrical activity and calcium homeostasis in pulmonary vein cardiomyocytes

Table 1 Action potential (AP) parameters of pulmonary vein cardiomyocytes treated with or without (control) arginine vasopressin (AVP) and/or AVP receptor antagonist (V1,OPC 21268 and V2 OPC 41061)

	APA (mV)	APD₇₅ (msec)	APD₅₀ (msec)	APD₂₀ (msec)	Beating rate interval (msec)	EDD (mV/msec)	LDD (mV/msec)	MDP (mV)	TP (mV)
Control, (n = 12)	80 ± 6	140 ± 13	99 ± 13	54 ± 8	453 ± 28	0.13 ± 0.05	0.21 ± 0.04	−55 ± 4	−39 ± 3
AVP (0.1 μM), (n = 11)	82 ± 8	164 ± 18	109 ± 16	65 ± 11	432 ± 35^#	0.08 ± 0.01	0.33 ± 0.05^#	−60 ± 2	−32 ± 5
AVP (1 μM), (n = 13)	71 ± 7	121 ± 12	82 ± 8	43 ± 5	305 ± 21*	0.09 ± 0.01	0.43 ± 0.06*	−53 ± 3	−32 ± 2
AVP (1 μM) + OPC 21268 (0.1 μM), (n = 11)	80 ± 6	131 ± 8	91 ± 7	48 ± 4	813 ± 213^#	0.08 ± 0.01	0.25 ± 0.03^#	−56 ± 4	−36 ± 3
AVP (1 μM) + OPC 41061 (10 nM), (n = 12)	90 ± 4	142 ± 4	104 ± 3	58 ± 4	329 ± 22*	0.11 ± 0.02	0.37 ± 0.02*	−54 ± 5	−36 ± 3
OPC 21268 (0.1 μM), (n = 10)	90 ± 4	148 ± 13	97 ± 10	57 ± 8	581 ± 100	0.09 ± 0.02	0.29 ± 0.03	−62 ± 3	−34 ± 3
OPC 41061 (10 nM), (n = 10)	94 ± 4	158 ± 9	118 ± 8	70 ± 5	468 ± 52^§	0.09 ± 0.01	0.24 ± 0.04^§	−59 ± 2	−30 ± 3

APD₇₅, APD₅₀, and APD₂₀ = AP duration at 75, 50 and 20% repolarization of the amplitude, EDD Early diastolic depolarization, LDD Late diastolic depolarization, MDP Maximum diastolic potential, TP Threshold potential. ^* P < 0.05 vs Control, ^# P < 0.05 vs AVP (1 μM), ^§ P < 0.05 OPC 41461 (10 nM) vs AVP (1 μM) + OPC 41461 (10 nM),